How to Navigate CDE Clinical Trial Approvals in China: 2026 Guide for Foreign Drug Developers
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) is the primary regulatory body responsible for reviewing and approving clinical trial applications — known as Investigational New Drug (IND) applications — for pharmaceutical products. Since China’s landmark 2017-2020 drug regulatory reforms, the CDE has transformed from a slow, unpredictable reviewer into a relatively efficient and internationally-aligned regulator, with IND approval timelines of 60 working days (silent approval) and increasing engagement with international standards through ICH membership and MRCT (multi-regional clinical trial) harmonization.
For foreign pharmaceutical and biotechnology companies, navigating CDE clinical trial approvals is the most critical step in accessing the Chinese market. This guide provides a comprehensive walkthrough of the CDE clinical trial approval process as of 2026, covering submission preparation, trial design considerations, ethics committee approvals, common regulatory pitfalls, and strategies for accelerated review.
The CDE’s Role in Clinical Trial Oversight
The CDE operates as a division of the NMPA’s Center for Drug Evaluation and is responsible for reviewing IND applications, NDA (New Drug Application) submissions, and supplemental applications for already-approved drugs. For clinical trials specifically, the CDE’s responsibilities include:
- IND review and approval: Evaluating the scientific validity, patient safety protections, and regulatory compliance of proposed clinical trials
- Trial protocol amendments: Reviewing and approving significant changes to ongoing clinical trials
- Clinical trial site qualification: Maintaining the national list of qualified clinical trial sites
- Safety data monitoring: Receiving and evaluating safety reports including SUSARs (Suspected Unexpected Serious Adverse Reactions) and DSMB (Data Safety Monitoring Board) reports
- GMP inspection coordination: Arranging inspections of clinical trial material manufacturing sites
- Guidance development: Publishing technical guidelines for clinical trial design, data management, and statistical analysis
As of 2026, the CDE employs approximately 850 reviewers organized into therapeutic area teams, with dedicated teams for oncology, cardiovascular, endocrine, neurology, anti-infective, and other major therapeutic categories. The CDE has significantly reduced reviewer turnover through improved compensation and career development pathways, resulting in more consistent and predictable review outcomes.
IND Application Types and Pathways
Type 1: Traditional IND (标准IND)
The standard pathway for most clinical trial applications. The sponsor submits a complete IND package including non-clinical pharmacology and toxicology data, clinical protocol, investigator’s brochure, and CMC data for the investigational product. The CDE conducts a full scientific review within 60 working days.
Best for: First-in-human (FIH) trials in China, drugs with no previous clinical data in Chinese populations, and complex drug modalities (biologics, gene therapies, cell therapies).
Type 2: MRCT IND (国际多中心临床试验IND)
For drugs already in global clinical development, the MRCT pathway allows sponsors to include Chinese trial sites in an ongoing global clinical trial program. The IND submission references the global clinical protocol with a China-specific appendix addressing ethnic sensitivity, local standard of care, and investigator qualifications.
Best for: Drugs in Phase II or Phase III global trials where Chinese site inclusion provides data for both global registration and Chinese NDA submission. The MRCT pathway is increasingly the preferred approach for foreign drug developers because it generates Chinese clinical data without requiring a separate China-specific trial, reducing both time and cost.
Type 3: Expedited Pathways (加速审评通道)
Several expedited pathways are available for drugs meeting specific criteria:
| Pathway | Criteria | Benefit |
|---|---|---|
| Breakthrough Therapy (突破性治疗药物) | Drug for serious condition with no effective treatment AND preliminary clinical evidence of substantial improvement over existing therapy | Enhanced CDE guidance, rolling review, priority NDA review |
| Priority Review (优先审评) | Drug on CDE priority review list (updated quarterly) including drugs for rare diseases, pediatric indications, and national health emergencies | Review timeline reduced to 130 working days (from 200) |
| Conditional Approval (附条件批准) | Drug for serious/life-threatening disease with surrogate endpoint data; requires post-market confirmatory study commitment | Earlier market access while confirmatory data is generated |
| Special Approval (特别审批) | Drugs for public health emergencies (pandemics, bioterrorism) | Most rapid pathway; can approve within weeks |
The CDE IND Review Process: Step by Step
Step 1: Pre-IND Communication (Recommended, Not Mandatory)
Foreign sponsors are strongly encouraged to request a pre-IND meeting with the CDE before formal submission, particularly for Class 1 innovative drugs and drugs with novel mechanisms of action. The pre-IND process:
- Submission: Submit a meeting request through the CDE’s online system, including a 30-50 page briefing package summarizing non-clinical data, clinical development plan, CMC overview, and specific questions for CDE guidance.
- Timeline: The CDE responds within 60 working days with either written feedback (the most common outcome) or a scheduled video conference meeting.
- Outcome: CDE feedback provides clear guidance on data gaps, trial design expectations, and submission requirements. Pre-IND feedback significantly reduces the risk of clinical hold on the subsequent IND submission.
- Cost: No CDE fee for pre-IND meetings. Preparation costs (consultant, regulatory affairs team) typically range USD 20,000-50,000.
Step 2: IND Submission
The formal IND application is submitted electronically through the CDE’s submission portal (药品业务应用系统). The submission must include:
- Application form (申请表) — Standardized CDE form with drug and sponsor information
- Non-clinical data summary — Pharmacology, pharmacokinetics, and toxicology data in CTD format (Module 2 and Module 4)
- Clinical protocol (临床试验方案) — Detailed protocol in Chinese or English, including inclusion/exclusion criteria, endpoints, statistical analysis plan, and stopping rules
- Investigator’s brochure (研究者手册) — Comprehensive summary of all available non-clinical and clinical data for the investigational drug
- CMC data — Drug substance and drug product specifications, manufacturing process, stability data, and GMP compliance documentation
- Informed consent form (知情同意书) — Template consent form in Chinese, written at an appropriate reading level for Chinese patients
- Certificate of Suitability (CoS) or equivalent — For imported investigational products, documentation of manufacturing authorization from the country of origin
The CDE charges a filing fee of RMB 5,000 per IND application (approximately USD 690) — significantly lower than the US FDA’s IND fee waiver (FDA does not charge IND review fees) but with similar overall cost when consultant and preparation expenses are included.
Step 3: CDE Review — The 60-Working-Day Clock
Upon receipt of a complete IND application, the CDE initiates a 60-working-day review. The review proceeds through three phases:
Phase 1 — Formality review (5 working days): The CDE’s submission management team checks for administrative completeness — correct forms, required attachments, complete data sets. Incomplete submissions are rejected without substantive review, and the sponsor must resubmit (the 60-day clock starts over).
Phase 2 — Scientific review (50 working days): The lead CDE reviewer (assigned by therapeutic area) conducts the substantive scientific evaluation, consulting with:
- Clinical pharmacology reviewer (PK/PD, dosing rationale)
- Toxicology reviewer (non-clinical safety assessment)
- CMC reviewer (drug quality, manufacturing consistency, stability)
- Statistics reviewer (trial design, sample size, endpoint validity)
- Medical reviewer (patient population, risk-benefit assessment)
Phase 3 — Decision (5 working days): The review team finalizes its recommendation. If no issues are identified, the IND is approved (silent approval — the sponsor receives no formal approval letter but may proceed when the 60-day period expires). If issues are identified, the CDE issues a “supplementary information notice” (补充资料通知) specifying the deficiencies.
Step 4: Responding to CDE Questions
If the CDE issues a question letter, the sponsor has 20 working days to respond. Common questions include:
- Additional toxicology data (e.g., 6-month chronic toxicity study when only 3-month data was provided)
- Clarification of ethnic sensitivity factors for the Chinese population
- Protocol amendments (e.g., dose selection rationale, exclusion criteria, stopping rules)
- Additional CMC data (e.g., impurity characterization, stability under Chinese climatic conditions)
- Informed consent form revisions (e.g., language simplifications, risk disclosure completeness)
Upon response submission, the CDE has 20 working days to review the response and either approve the IND or request additional information. The average IND receives 1-2 rounds of CDE questions before approval.
Step 5: Ethics Committee (EC) Approval
IND approval from the CDE is necessary but not sufficient to begin patient enrollment. Each clinical trial site must also obtain approval from its local ethics committee (EC). Key facts about the EC approval process in China:
- Local vs. central EC: Unlike the US single IRB model, China requires each participating trial site to obtain local EC approval. While the 2020 reforms introduced a “centralized EC review mechanism” (伦理审查互认) for multi-site trials, participation in mutual recognition agreements remains voluntary for individual institutions as of 2026.
- Timeline: Local EC approval typically takes 30-60 days for initial review, with amendments and expedited reviews taking 10-20 days.
- Documentation: ECs require the CDE IND approval (or confirmation of silent approval), the informed consent form, investigator’s brochure, clinical protocol, investigator qualifications, and site GCP compliance documentation.
- Language: All EC submission materials must be in Chinese. Foreign-language documents (investigator’s brochure, protocol) require certified Chinese translations.
CDE Clinical Trial Approval Quick-Reference Checklist
Follow this ordered checklist to ensure you complete every step of the CDE clinical trial approval process without missing critical submissions or deadlines.
- Request pre-IND meeting with CDE — Prepare and submit a briefing package covering non-clinical data, clinical development plan, CMC overview, and specific regulatory questions. Schedule the meeting or obtain written feedback within 60 working days.
- Prepare complete IND submission package — Compile all required documents in CDE-acceptable format: application form, non-clinical data, clinical protocol, investigator’s brochure, CMC data, informed consent form, and CoS documentation.
- Submit IND through CDE electronic portal — File the complete application and pay the RMB 5,000 filing fee. Monitor for formality review completion within 5 working days.
- Respond to CDE questions within 20 working days — If the CDE issues a supplementary information notice, prepare a comprehensive response addressing each deficiency. Track the 20-working-day deadline strictly — extensions are not granted.
- Obtain CDE IND approval confirmation — Document the silent approval date (60 working days from submission) or formal approval letter if questions were resolved. Record the CDE-approved clinical protocol version.
- Submit to local ethics committees at each trial site — Prepare Chinese-language EC submission packages. Submit to all participating sites simultaneously but anticipate variable review timelines (30-60 days per site).
- Register the trial on ChiCTR — Complete Chinese Clinical Trial Registry registration before enrolling the first patient. ChiCTR registration is a legal requirement under PRC law.
- Begin patient enrollment with CDE-approved protocol — Confirm all sites have EC approval. Implement the clinical trial per CDE-approved protocol. Submit protocol amendments to CDE and ECs for any significant changes. Initiate safety reporting per Chinese SUSAR timelines.
Strategic Considerations for Foreign Sponsors
MRCT vs. China-Only Trials: Making the Right Choice
For foreign drug developers, the most consequential strategic decision is whether to include Chinese trial sites in an existing global MRCT program or to conduct a separate China-only clinical trial. Factors favoring each approach:
| Factor | Favor MRCT | Favor China-Only Trial |
|---|---|---|
| Drug development stage | Phase II or III global trial ongoing | Early stage (Phase I) or China-first strategy |
| Ethnic sensitivity | Low predicted ethnic differences | Significant ethnic PK/PD differences expected |
| Chinese patient availability | Standard indication with large patient pool | Rare disease requiring specialized centers |
| Standard of care alignment | Chinese standard of care similar to global | Significant differences in SOC (e.g., TCM integration) |
| Time to market | Faster — data generated in parallel | Slower — sequential trial execution |
| Cost | Lower — shared global trial infrastructure | Higher — dedicated Chinese infrastructure |
The CDE has increasingly embraced MRCT data for Chinese registration, provided the MRCT includes an adequate representation of Chinese patients (typically 10-20% of the total study population or a pre-specified minimum of 80-120 patients) and the sponsor conducts an ethnic sensitivity analysis demonstrating that the drug’s PK/PD profile does not differ significantly between Chinese and non-Chinese populations.
CRO Selection and Site Management
Selecting the right China-based CRO is critical to clinical trial success. Key evaluation criteria:
- Therapeutic area expertise: Does the CRO have experience conducting trials in your specific indication?
- Site relationships: Does the CRO have established relationships with top-tier clinical trial centers in your therapeutic area?
- Regulatory track record: How many CDE IND submissions has the CRO managed, and what is their first-pass approval rate?
- Data management systems: Does the CRO’s EDC system comply with both CDE requirements and your global data standards?
- English-language capability: Can the CRO provide documentation and communication in English acceptable for global regulatory filing?
Common Pitfalls in CDE Clinical Trial Approvals
Insufficient ethnic sensitivity data. The CDE requires a formal ethnic sensitivity analysis comparing Chinese and non-Chinese populations for PK/PD parameters, safety profiles, and dose-response relationships. Sponsors who submit global clinical data without this analysis face extended review cycles or outright rejection. Commission an ethnic sensitivity package from a qualified clinical pharmacology consultant before submitting your IND.
Inadequate CMC data for Chinese climatic conditions. China’s diverse climate (ranging from subarctic Heilongjiang to subtropical Guangdong) requires specific stability testing conditions that may differ from ICH Q1A standards. The ChP requires 40°C/75% RH accelerated stability testing, and for products with moisture sensitivity, additional testing under 25°C/60% RH long-term conditions is recommended.
Underestimating ethics committee timelines. While CDE review follows a predictable 60-working-day timeline, local EC approvals are highly variable. Sites that have not participated in international clinical trials before may take 90+ days for initial review. Build 12-16 weeks for EC approvals into your trial timeline and initiate site selection and EC preparation as early as possible.
Overlooking informed consent form requirements. Chinese regulations require informed consent forms to be written at a level understandable to patients with low health literacy. Complex scientific language that would be acceptable in US or EU consent forms is frequently rejected by Chinese ECs. Engage a medical writer with Chinese EC experience to draft the consent form.
GCP compliance gaps at trial sites. The CDE has increased its GCP inspection frequency in recent years, with approximately 15-20% of clinical trial sites receiving an inspection during the trial period. Common findings include inadequate source document verification, protocol deviation documentation deficiencies, and investigational product accountability gaps. Ensure your CRO conducts a pre-trial GCP readiness assessment for each site.
Where to Go From Here
For foreign drug developers considering clinical trial initiation in China, the first practical step is a pre-IND meeting with the CDE. This meeting provides authoritative guidance on data requirements, trial design, and submission strategy, and significantly reduces the risk of IND rejection or extended review. For drugs already in global Phase II or III trials, the MRCT pathway — adding Chinese trial sites to your existing global program — is typically the fastest and most cost-effective approach. Engage a China-based regulatory affairs consultant or CRO early in the planning process to conduct a gap analysis and develop your CDE engagement strategy.
Last updated: July 2026. CDE policies and procedures reflect NMPA regulations in effect as of mid-2026. Always verify current submission requirements and review timelines with the CDE’s official guidance documents or a qualified regulatory affairs professional before initiating a submission.
